BriaCell Therapeutics Corp. financial data

Symbol
BCTX, BCTXW on Nasdaq
Location
3 Rd Floor, Bellevue Centre, 235 15 Th Str, West Vancouver, British Columbia, Canada
State of incorporation
British Columbia, Canada
Fiscal year end
July 31
Former names
Ansell Capital Corp. (to 6/20/2014)
Latest financial report
10-Q - Q1 2024 - Jun 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 463 % -87.2%
Return On Equity 152 %
Return On Assets -37.4 % +26.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18.3M shares +14.4%
Common Stock, Shares, Outstanding 16M shares +2.99%
Entity Public Float 105M USD +18.7%
Common Stock, Value, Issued 69.6M USD +6.1%
Weighted Average Number of Shares Outstanding, Basic 16M shares +2.99%
Weighted Average Number of Shares Outstanding, Diluted 16M shares +2.99%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 27.9M USD +109%
General and Administrative Expense 7.33M USD -1.8%
Operating Income (Loss) -35.3M USD -69.6%
Nonoperating Income (Expense) 29.2M USD +1085%
Net Income (Loss) Attributable to Parent -6M USD +67.3%
Earnings Per Share, Basic -0.36 USD/shares
Earnings Per Share, Diluted -1.24 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 936K USD -96.7%
Accounts Receivable, after Allowance for Credit Loss, Current 15.2K USD +2.26%
Assets, Current 5.53M USD -81.3%
Property, Plant and Equipment, Net 2.5K USD 0%
Assets 6.2M USD -79.1%
Liabilities, Current 6.76M USD +389%
Accumulated Other Comprehensive Income (Loss), Net of Tax -139K USD 0%
Retained Earnings (Accumulated Deficit) -84.2M USD -7.66%
Stockholders' Equity Attributable to Parent -3.78M USD -137%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -6.23M USD -5.78%
Liabilities and Equity 6.2M USD -79.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.61M USD -115%
Net Cash Provided by (Used in) Financing Activities -47.3K USD
Common Stock, Shares, Issued 16M shares +2.99%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 936K USD -96.7%
Deferred Tax Assets, Valuation Allowance 15.9M USD +31.2%
Deferred Tax Assets, Gross 16M USD +31.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -4.9M USD +51.1%
Deferred Tax Assets, Operating Loss Carryforwards 4.91M USD +22.4%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 7.92M USD
Depreciation, Depletion and Amortization 3.82K USD +0.03%
Deferred Tax Assets, Net of Valuation Allowance 45.2K USD -6.64%
Share-based Payment Arrangement, Expense 392K USD +39.5%